Top

Published in:

01-03-2021 | Rhabdomyosarcoma | Case Reports

FET(EWSR1)-TFCP2 Rhabdomyosarcoma: An Additional Example of this Aggressive Variant with Predilection for the Gnathic Bones

Authors: Ioannis G. Koutlas, Damon R. Olson, Jawhar Rawwas

Published in: Head and Neck Pathology | Issue 1/2021

Abstract

An example of a mandibular rhabdomyosarcoma in a 15-year-old male is described featuring EWSR1-TFCP2 fusion with homolateral lymph node metastasis and apparent metastasis to the thoracic vertebra T7. This type of rhabdomyosarcoma has preference for the craniofacial skeleton. Histologically, the tumor was composed of spindle and epithelioid cells characterized by nuclear pleomorphism, cytologic atypia and brisk mitotic activity. Immunohistochemically, it featured diffuse positive nuclear staining MYOD1, only focal staining for myogenin and patchy cytoplasmic staining for desmin. Tumor cells were positive for keratins and nuclear staining for SATB2 was also observed. Interestingly, tumor cells were diffusely positive for calponin. Currently, the patient is under chemotherapy treatment.

Miettinen M, Fetch JF, Antonescu CR, Folpe AL, Wakely PE Jr. Rhabdomyosarcoma. In: Miettinen M, Fetch JF, Antonescu CR, Folpe AL, Wakely Jr PE, editors. Tumors of the soft tissues. AFIP Atlas Of Tumor Pathology. 4th ed. Silver Spring, MD: American Registry of Pathology; 2014. pp. 291–304

Kohashi K, Kinoshita I, Oda Y. Soft tissue special issue: skeletal muscle tumors: a clinicopathological review. Head Neck Pathol. 2020;14:12–20.CrossRef

Alaggio R, Zhang L, Sung Y-S, et al. A Molecular study of pediatric spindle and sclerosing rhabdomyosarcoma: identification of novel and recurrent VGLL2-related fusions in infantile cases. Am J Surg Pathol. 2016;40:224–35.CrossRef

Agaram N, LaQuaglia MP, Alaggio R, et al. MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification. Mod Pathol. 2019;32:27–36.CrossRef

Karanian M, Pissaloux D, Gomez-Brouchet A, et al. SRF-FOXO1 and SRF-NCOA1 fusion genes delineate a distinctive subset of well-differentiated rhabdomyosarcoma. Am J Surg Pathol. 2020;44:607–16.CrossRef

Watson S, Perrin V, Guillemot D, et al. Transcriptomic definition of molecular subgroups of small round cell sarcomas. J Pathol. 2018;245:29–40.CrossRef

Dashti NK, Wehrs RN, Thomas BC, et al. Spindle cell rhabdomyosarcoma of bone with FUS-TFCP2 fusion: confirmation of a very recently described rhabdomyosarcoma subtype. Histopathol. 2018;73:514–20.CrossRef

Agaram N, Zhang L, Sung Y-S, et al. Expanding the spectrum of intraosseous rhabdomyosarcoma. Correlation between 2 distinct gene fusions and phenotype. Am J Surg Pathol. 2019;43:695–702.CrossRef

Le Loarer F, Cleven AHG, Bouvier C, et al. A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation. Mod Pathol. 2020;33:404–19.CrossRef

10.

Kovar H. Dr. Jeckyll and Mr. Hyde: the two faces of the FUS/EWS/TAF15 protein family. Sarcoma. 2011;2011:837474.CrossRef

11.

Zhu G, Benayed R, Ho C, et al. Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma. Mod Pathol. 2019;32:609–20.CrossRef

12.

Flaitz CM, Hicks MJ. Primary intraosseous rhabdomyosarcoma: rare subtype involving mandible with unique translocation. 74th Annual Meeting, American Academy of Oral and Maxillofacial Pathology, Nashville; Abstract ID:43; poster No:55; 2020

13.

Leinweber B, Tang JX, Stafford WF, Chalovich JM. Calponin interaction with alpha-actinin-actin: evidence for a structural role for calponin. Biophys J. 1999;77:3208–17.CrossRef

14.

Michal M, Rubin BP, Kazakov DV, et al. Inflammatory leiomyosarcoma shows frequent co-expression of smooth and skeletal muscle markers supporting a primitive myogenic phenotype: a report of 9 cases with a proposal for reclassification as low-grade inflammatory myogenic tumor. Virchows Arch. 2020. https://doi.org/10.1007/s00428-020-02774-z.CrossRefPubMed

15.

de Aguiar MCF, de Noronha MS, Silveira RL, et al. Epithelioid rhabdomyosarcoma: report of the first case in the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020. https://doi.org/10.1016/j.oooo.2020.01.004.CrossRefPubMed

16.

Davis JL, Horvai AE. Special AT-rich sequence-binding protein 2 (SATB2) expression is sensitive but may not be specific for osteosarcoma as compared with other high-grade primary bone sarcomas. Histopathology. 2016;69:84–90.CrossRef

17.

Hornick JL. Novel uses of immunohistochemistry in the diagnosis and classification of soft tissue tumors. Mod Pathol. 2014;27(Suppl 1):47–63.CrossRef

18.

Addison WN, Hall KC, Matsubara T, et al. Zfp423 regulates skeletal muscle regeneration and proliferation. Mol Cell Biol. 2019;39:e00447–e518. https://doi.org/10.1128/MCB.00447-18.CrossRefPubMedPubMedCentral

19.

Brunac AC, Laprie A, Castex MP, et al. The combination of radiotherapy and ALK inhibitors is effective in the treatment of intraosseous rhabdomyosarcoma with FUS-TFCP2 fusion transcript. Periatr Blood Cancer. 2020;67:e28185. https://doi.org/10.1002/pbc.28185.CrossRef

20.

Zhou X, Hao Q, Lu H. Mutant p53 in cancer therapy-the barrier or the path. J Mol Cell Biol. 2019;11:293–305.CrossRef

21.

Andersson MK, Ståhlberg S, Arvidsson Y, et al. The multifunctional FUS, EWS and TAF15 proto-oncoproteins show cell type-specific expression pattercs and involvement in cell spreading and stress response. BMC Cell Biol. 2008;9:37. https://doi.org/10.1186/1471-2121-9-37.CrossRefPubMedPubMedCentral

22.

Charville GW, Wang W-L, Ingram DR, et al. EWSR1 fusion proteins mediate PAX7 expression in Ewing sarcoma. Mod Pathol. 2017;30:1312–20.CrossRef

23.

Sirvent N, Trassard M, Ebran N, Attias R, Pedeutour F. Fusion of EWSR1 with the DUX4 facioscapulohumeral muscular dystrophy region resulting from t(4;22)(q35;q12) in a case of embryonal rhabdomyosarcoma. Cancer Genet Cytogenet. 2009;195:12–8.CrossRef

24.

Kotarba G, Krzywinska E, Grabowska AI, Taracha A, Wilanowski T. TFCP2/TFCP2L1/UBP1 transcription factors in cancer. Cancer Lett. 2018;420:72–9.CrossRef

25.

Taracha A, Kotarba G, Wilanowski T. Neglected functions of TFCP2/TFCP2L1/UBP1 transcription factors may offer valuable insights into their mechanisms of action. Int J Mol Sci. 2018;19:E2852. https://doi.org/10.3390/ijms19102852.CrossRefPubMed

26.

Porta-de-la-Riva M, Stanisavljevic J, Curto J, et al. TFCP2c/LSF/LBP-1c is required for Snail1-induced fibronectin gene expression. Biochem J. 2011;435:563–8.CrossRef

27.

Zhao Y, Kaushik N, Kang JH, et al. A feedback loop comprising EGF/TGF-α sustains TFCP2-mediated breast cancer progression. Cancer Res. 2020. https://doi.org/10.1158/0008-5472.CAN-19-2908.CrossRefPubMedPubMedCentral

28.

Yoo BK, Emdad L, Gredler R, et al. Transcription factor Late SV40 Factor (LSF) functions as an oncogene in hepatocellular carcinoma. Proc Natl Acad Sci USA. 2010;107:8357–62.CrossRef

29.

Yuedi D, Yuankun C, Jiaying Z, et al. TFCP2 activates beta-catenin/TCF signaling in the progression of pancreatic cancer. Oncotarget. 2017;8:70538–49.CrossRef

30.

Chen C-H, Tsai H-T, Chuang H-C, et al. Metformin disrupts malignant behavior of oral squamous cell carcinoma via a novel signaling involving late SV40 factor/Aurora A. Sci Rep. 2017;7:1358.CrossRef

31.

Goto Y, Yajima I, Kumasaka M, et al. Transforming factor LSF (TFCP2) inhibits melanoma growth. Oncotarget. 2016;7:2379–90.CrossRef

32.

Pulling LC, Grimes MJ, Damiani LA, et al. Dual promoter regulation of death-associated protein kinase gene leads to differentially silenced transcripts by methylation in cancer. Carcinogenesis. 2009;30:2023–30.CrossRef

33.

Kang HC, Chae JH, Kim BS, et al. Transcription factor CP2 is involved in activating mBMP4 in mouse mesenchymal stem cells. Mol Cells. 2004;17:454–61.PubMed

Title: FET(EWSR1)-TFCP2 Rhabdomyosarcoma: An Additional Example of this Aggressive Variant with Predilection for the Gnathic Bones
Authors: Ioannis G. Koutlas
Damon R. Olson
Jawhar Rawwas
Publication date: 01-03-2021
Publisher: Springer US
Keyword: Rhabdomyosarcoma
Published in: Head and Neck Pathology / Issue 1/2021
Electronic ISSN: 1936-0568
DOI: https://doi.org/10.1007/s12105-020-01189-1

ACC 2024 Congress

Springer Medicine

FET(EWSR1)-TFCP2 Rhabdomyosarcoma: An Additional Example of this Aggressive Variant with Predilection for the Gnathic Bones

Abstract

ACC 2024 Congress

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Gingival Swelling as the Initial Manifestation of Granulomatosis with Polyangiitis

Rosai–Dorfman Disease: A Rare Clinicopathological Presentation and Review of the Literature

Ectopic Cervical Thyroid Tissue Affected by Fibrosing Hashimoto’s Thyroiditis Mimicking Multifocal Metastatic Papillary Thyroid Carcinoma—A Hard Lesson Learnt from an Unusual Case

Primary Parotid Merkel Type Small Cell Neuroendocrine Carcinoma with Oligometastasis to the Brain and Adrenal Gland: Case Report and Review of Literature

Central Odontogenic Fibroma with Giant Cell Granuloma-Like Lesion: A Report of an Additional Case and Review of Literature

Multifocal Parotid Oncocytic Cystadenomatosis: A Rare Process that Can Mimic Malignancy